Wall Street brokerages predict that Encompass Health Co. (NYSE: EHC – Get Rating) will report $ 1.00 earnings per share for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Encompass Health’s earnings. The highest EPS estimate is $ 1.07 and the lowest is $ 0.96. Encompass Health reported earnings per share of $ 1.17 during the same quarter last year, which suggests a negative year-over-year growth rate of 14.5%. The business is expected to issue its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Encompass Health will report full year earnings of $ 4.11 per share for the current fiscal year, with EPS estimates ranging from $ 4.05 to $ 4.19. For the next year, analysts anticipate that the company will report earnings of $ 4.53 per share, with EPS estimates ranging from $ 4.37 to $ 4.70. Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that follow Encompass Health.
Encompass Health (NYSE: EHC – Get Rating) last announced its earnings results on Wednesday, April 27th. The company reported $ 0.97 earnings per share for the quarter, beating the consensus estimate of $ 0.93 by $ 0.04. The company had revenue of $ 1.33 billion during the quarter, compared to the consensus estimate of $ 1.32 billion. Encompass Health had a return on equity of 17.99% and a net margin of 7.51%. The company revenue was up 8.4% on a year-over-year basis. During the same period last year, the firm earned $ 1.05 earnings per share.
Several brokerages have recently weighed in on EHC. TheStreet upgraded Encompass Health from a “c +” rating to a “b-” rating in a research note on Tuesday, March 15th. Zacks Investment Research upgraded Encompass Health from a “sell” rating to a “hold” rating and set a $ 76.00 price target for the company in a research note on Monday, April 11th. StockNews.com upgraded Encompass Health from a “hold” rating to a “buy” rating in a research note on Thursday, June 2nd. Finally, Truist Financial lifted their price target on Encompass Health from $ 78.00 to $ 85.00 in a research note on Thursday, April 7th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $ 83.89.
Shares of Encompass Health stock opened at $ 61.37 on Wednesday. The business has a 50-day moving average of $ 67.56 and a 200-day moving average of $ 65.88. The company has a debt-to-equity ratio of 1.32, a current ratio of 1.26 and a quick ratio of 1.26. The company has a market capitalization of $ 6.12 billion, a PE ratio of 15.70, a P / E / G ratio of 2.16 and a beta of 0.96. Encompass Health has a 1-year low of $ 56.31 and a 1-year high of $ 85.75.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 20th. Shareholders of record on Wednesday, July 13th will be paid a $ 0.28 dividend. The ex-dividend date is Tuesday, July 12th. This represents a $ 1.12 dividend on an annualized basis and a yield of 1.82%. Encompass Health’s payout ratio is currently 28.64%.
In related news, Director Kevin J. O’connor bought 1,000 shares of the firm’s stock in a transaction on Friday, May 6th. The stock was bought at an average cost of $ 66.48 per share, for a total transaction of $ 66,480.00. Following the completion of the purchase, the director now directly owns 3,436 shares in the company, valued at approximately $ 228,425.28. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 2.70% of the company stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. raised its holdings in shares of Encompass Health by 1.4% during the fourth quarter. BlackRock Inc. now owns 10,643,463 shares of the company stock valued at $ 694,594,000 after buying an additional 145,130 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Encompass Health by 5.8% during the third quarter. Wellington Management Group LLP now owns 8,181,371 shares of the company stock valued at $ 613,929,000 after buying an additional 450,688 shares during the last quarter. Baupost Group LLC MA raised its holdings in shares of Encompass Health by 318.9% during the first quarter. Baupost Group LLC MA now owns 3,000,000 shares of the company stock valued at $ 213,330,000 after buying an additional 2,283,900 shares during the last quarter. State Street Corp raised its holdings in shares of Encompass Health by 5.0% during the first quarter. State Street Corp now owns 2,733,254 shares of the company stock valued at $ 195,118,000 after buying an additional 130,504 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in shares of Encompass Health by 33.3% during the first quarter. Bank of New York Mellon Corp now owns 2,099,763 shares of the company stock valued at $ 149,314,000 after buying an additional 524,766 shares during the last quarter. 91.70% of the stock is currently owned by institutional investors.
About Encompass Health: (Get Rating)
Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.
Get a free copy of the Zacks research report on Encompass Health (EHC)
For more information about research offers from Zacks Investment Research, visit Zacks.com:
Receive News & Ratings for Encompass Health Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Encompass Health and related companies with MarketBeat.com’s FREE daily email newsletter.